FATE – Fate Therapeutics, Inc.
Float Short %
8.82
Margin Of Safety %
Put/Call OI Ratio
0.18
EPS Next Q Diff
0.04
EPS Last/This Y
0.56
EPS This/Next Y
0.1
Price
0.96
Target Price
4.45
Analyst Recom
2.25
Performance Q
-31.21
Relative Volume
0.94
Beta
2.31
Ticker: FATE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | FATE | 1.08 | 0.10 | 0.00 | 6217 |
| 2025-08-18 | FATE | 1.19 | 0.14 | 1.13 | 2825 |
| 2025-08-19 | FATE | 1.14 | 0.17 | 0.00 | 2979 |
| 2025-08-20 | FATE | 1.125 | 0.16 | 0.00 | 3240 |
| 2025-08-21 | FATE | 1.12 | 0.16 | 0.86 | 3254 |
| 2025-08-22 | FATE | 1.145 | 0.17 | 0.07 | 3317 |
| 2025-08-25 | FATE | 1.08 | 0.17 | 0.00 | 3456 |
| 2025-08-26 | FATE | 1.105 | 0.17 | 0.00 | 3462 |
| 2025-08-27 | FATE | 1.115 | 0.17 | 25.00 | 3460 |
| 2025-08-28 | FATE | 1.085 | 0.18 | 0.00 | 3485 |
| 2025-08-29 | FATE | 1.045 | 0.18 | 999.99 | 3487 |
| 2025-09-02 | FATE | 1.035 | 0.18 | 0.00 | 3488 |
| 2025-09-03 | FATE | 1 | 0.18 | 0.33 | 3491 |
| 2025-09-04 | FATE | 0.9735 | 0.18 | 0.04 | 3493 |
| 2025-09-05 | FATE | 1.005 | 0.18 | 10.00 | 3502 |
| 2025-09-08 | FATE | 0.9661 | 0.18 | 1.03 | 3503 |
| 2025-09-09 | FATE | 0.9785 | 0.18 | 0.00 | 3533 |
| 2025-09-10 | FATE | 1 | 0.18 | 0.00 | 3539 |
| 2025-09-11 | FATE | 1.015 | 0.17 | 1.30 | 3611 |
| 2025-09-12 | FATE | 0.9621 | 0.18 | 3.29 | 3661 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | FATE | 1.09 | -4.3 | - | -1.12 |
| 2025-08-18 | FATE | 1.18 | 30.7 | - | -1.12 |
| 2025-08-19 | FATE | 1.14 | 30.7 | - | -1.12 |
| 2025-08-20 | FATE | 1.12 | 30.7 | - | -1.12 |
| 2025-08-21 | FATE | 1.12 | 30.7 | - | -1.12 |
| 2025-08-22 | FATE | 1.14 | 31.2 | - | -1.11 |
| 2025-08-25 | FATE | 1.09 | 31.2 | - | -1.11 |
| 2025-08-26 | FATE | 1.11 | 31.2 | - | -1.11 |
| 2025-08-27 | FATE | 1.12 | 31.2 | - | -1.11 |
| 2025-08-28 | FATE | 1.09 | 31.2 | - | -1.11 |
| 2025-08-29 | FATE | 1.04 | 31.2 | - | -1.11 |
| 2025-09-02 | FATE | 1.04 | 31.2 | - | -1.08 |
| 2025-09-03 | FATE | 1.00 | 31.2 | - | -1.08 |
| 2025-09-04 | FATE | 0.97 | 31.2 | - | -1.08 |
| 2025-09-05 | FATE | 1.01 | 31.2 | - | -1.08 |
| 2025-09-08 | FATE | 0.97 | 31.2 | - | -1.08 |
| 2025-09-09 | FATE | 0.98 | 31.2 | - | -1.08 |
| 2025-09-10 | FATE | 1.00 | 31.2 | - | -1.08 |
| 2025-09-11 | FATE | 1.02 | 31.2 | - | -1.08 |
| 2025-09-12 | FATE | 0.96 | 31.2 | - | -1.08 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | FATE | -0.31 | -7.84 | 8.61 |
| 2025-08-18 | FATE | -0.31 | -17.13 | 8.48 |
| 2025-08-19 | FATE | -0.40 | -17.13 | 8.48 |
| 2025-08-20 | FATE | -0.40 | -17.13 | 8.48 |
| 2025-08-21 | FATE | -0.40 | -17.13 | 8.48 |
| 2025-08-22 | FATE | -0.40 | -17.13 | 8.48 |
| 2025-08-25 | FATE | -0.40 | -20.13 | 8.48 |
| 2025-08-26 | FATE | -0.40 | -20.13 | 8.48 |
| 2025-08-27 | FATE | -0.40 | -20.13 | 8.59 |
| 2025-08-28 | FATE | -0.40 | -20.13 | 8.59 |
| 2025-08-29 | FATE | -0.40 | -20.13 | 8.59 |
| 2025-09-02 | FATE | -0.40 | -20.25 | 8.59 |
| 2025-09-03 | FATE | -0.40 | -20.25 | 8.59 |
| 2025-09-04 | FATE | -0.40 | -20.25 | 8.59 |
| 2025-09-05 | FATE | -0.40 | -20.25 | 8.59 |
| 2025-09-08 | FATE | -0.40 | -20.24 | 8.59 |
| 2025-09-09 | FATE | -0.40 | -20.24 | 8.59 |
| 2025-09-10 | FATE | -0.40 | -20.24 | 8.59 |
| 2025-09-11 | FATE | -0.40 | -20.24 | 8.82 |
| 2025-09-12 | FATE | -0.40 | -20.24 | 8.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.29
Avg. EPS Est. Current Quarter
-0.28
Avg. EPS Est. Next Quarter
-0.24
Insider Transactions
-0.4
Institutional Transactions
-20.24
Beta
2.31
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
14
Growth Score
24
Sentiment Score
29
Actual DrawDown %
99.2
Max Drawdown 5-Year %
-99.4
Target Price
4.45
P/E
Forward P/E
PEG
P/S
13.11
P/B
0.42
P/Free Cash Flow
EPS
-1.45
Average EPS Est. Cur. Y
-1.08
EPS Next Y. (Est.)
-0.99
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2025.05
Relative Volume
0.94
Return on Equity vs Sector %
-90.5
Return on Equity vs Industry %
-77.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.21
EBIT Estimation
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading